Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including STERIS (NYSE:STE) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including CONMED (NYSE:CNMD) and its peers.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Although STERIS (currently trading at $259.38 per share) has gained 7.1% over the last six months, it has trailed the S&P 500’s 14.4% return during that period. This may have investors wondering how to approach the situation.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - diversified stocks, including BD (NYSE:BDX) and its peers.
Shares of medical equipment and services company Steris (NYSE:STE).
jumped 8.6% in the morning session after the company reported strong third-quarter 2025 results that beat expectations and raised its full-year financial outlook. For the quarter, revenues grew nearly 10% from the previous year to $1.46 billion, while adjusted earnings per share increased by 15.4% to $2.47. Both of these key figures surpassed analyst estimates. Looking ahead, STERIS provided a more optimistic forecast, lifting its expected adjusted earnings for the full year to a range of $10.15 to $10.30 per share.
Medical equipment and services company Steris (NYSE:STE). reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 9.9% year on year to $1.46 billion. Its non-GAAP profit of $2.47 per share was 5.1% above analysts’ consensus estimates.
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
Even though STERIS (currently trading at $242.37 per share) has gained 8.3% over the last six months, it has lagged the S&P 500’s 24.7% return during that period. This might have investors contemplating their next move.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q2, starting with Zimmer Biomet (NYSE:ZBH).
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including STERIS (NYSE:STE) and its peers.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Medical equipment and services company Steris (NYSE:STE). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 8.7% year on year to $1.39 billion. Its non-GAAP profit of $2.34 per share was 3.4% above analysts’ consensus estimates.
